INO-A002 Zika Vaccine Description 2022
INO-A002 is a DNA-encoded monoclonal antibody (dMAb™) technology candidate.
INO-A002 is indicated to prevent or treat the Zika virus infection.
The vaccine will be delivered as an intramuscular (IM) injection followed by electroporation with the CELLECTRA® 2000 device.
When delivered directly into the body, the genetic codes provided by the synthetic dMAbs instruct the body's cells to become the factory that manufactures the therapeutic antibody products.
INO-A002 News 2019 - 2022
February 20, 2019 - Inovio Pharmaceuticals, Inc. in collaboration with The Wistar Institute and the University of Pennsylvania announced that the first subject was dosed as part of the first-ever human study of Inovio's DNA-encoded monoclonal antibody (dMAb™) technology.
INO-A002 Clinical Trial
INO-A002 is currently in a Phase 1 clinical trial.
The trial is led by Pablo Tebas, M.D., Professor of Medicine at the Hospital of the University of Pennsylvania.